Skip to main content
TL

Triad Life Sciences

Triad Life Sciences develops the InnovaMatrix® platform, which utilizes placental-derived extracellular matrix technology to create FDA-cleared medical devices for chronic wound management. This technology addresses the limitations of traditional human placental grafts by providing reliable, reproducible, and cost-effective solutions for complex surgical wounds and hard-to-heal injuries.

Collierville, United StatesFounded 2017161K+ followers
Updated 4 months ago

Funding

$18.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional human placental grafts for wound management can suffer from variability in source material and processing, leading to inconsistent product performance and reliability. This variability can impact the effectiveness of wound healing and increase costs associated with unpredictable outcomes.

Solution

Triad Life Sciences develops the InnovaMatrix platform, which leverages placental-derived extracellular matrix (ECM) technology to create medical devices for chronic wound management. The InnovaMatrix platform addresses the limitations of traditional placental grafts by providing reliable, reproducible, and cost-effective ECM products. These products are regulated as medical devices and manufactured under Current Good Manufacturing Practice (CGMP) standards, ensuring consistency and a rigorous safety profile. The platform aims to advance wound management and burn care by combining the technological advantages of a medical device with the inherent structural benefits of the placenta.

Target Audience

The primary customers are healthcare providers, including surgeons and wound care specialists, who require reliable and cost-effective solutions for managing acute and chronic wounds.

Features

  • Placental-derived extracellular matrix (ECM) technology
  • Products regulated as medical devices
  • Manufactured under Current Good Manufacturing Practice (CGMP)
  • Consistent source material and proprietary processing technology to reduce material variance
  • Designed for complex surgical wounds, hard-to-heal wounds, burns, and other regenerative dermal applications
This profile is AI-generated and may contain inaccuracies.